Abstract | BACKGROUND: METHODS: Prospective randomized trials evaluating therapy with or without anti-EGFR agents in NSCLC patients. Data on VTEs and ATEs were extracted. RESULTS: A total of 8,410 patients from 12 trials were included for analysis. Anti-EGFR agents significantly increased the risk of all-grade and high-grade VTEs (Peto OR 1.50, 95%CI 1.16-1.95, P = 0.002; Peto OR 1.73, 95%CI: 1.32-2.26, p < 0.001, respectively), but not for all-grade and high-grade ATEs. CONCLUSION: The use of anti-EGFR agents significantly increased the risk of all-grade and high-grade VTEs but not for ATEs in NSCLC patients.
|
Authors | Jian Zheng, Xiaoru Bai, Chengyu Hong, Hong Gao, Xiaoling Li |
Journal | Expert review of clinical pharmacology
(Expert Rev Clin Pharmacol)
Vol. 9
Issue 10
Pg. 1389-1395
(Oct 2016)
ISSN: 1751-2441 [Electronic] England |
PMID | 27494194
(Publication Type: Journal Article)
|